JP2022512540A - Ｆｌｔ３ｌ系キメラタンパク質 - Google Patents

Ｆｌｔ３ｌ系キメラタンパク質 Download PDF

Info

Publication number
JP2022512540A
JP2022512540A JP2021511583A JP2021511583A JP2022512540A JP 2022512540 A JP2022512540 A JP 2022512540A JP 2021511583 A JP2021511583 A JP 2021511583A JP 2021511583 A JP2021511583 A JP 2021511583A JP 2022512540 A JP2022512540 A JP 2022512540A
Authority
JP
Japan
Prior art keywords
chimeric protein
cells
domain
extracellular domain
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511583A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020047327A5 (https=
JP2022512540A5 (https=
Inventor
シュライバー、テイラー
フロム、ジョージ
シルバ、スレシュ デ
Original Assignee
シャタック ラボ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ，インコーポレイテッド filed Critical シャタック ラボ，インコーポレイテッド
Publication of JP2022512540A publication Critical patent/JP2022512540A/ja
Publication of JPWO2020047327A5 publication Critical patent/JPWO2020047327A5/ja
Publication of JP2022512540A5 publication Critical patent/JP2022512540A5/ja
Priority to JP2024075517A priority Critical patent/JP2024096361A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021511583A 2018-08-29 2019-08-29 Ｆｌｔ３ｌ系キメラタンパク質 Pending JP2022512540A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075517A JP2024096361A (ja) 2018-08-29 2024-05-07 Ｆｌｔ３ｌ系キメラタンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724596P 2018-08-29 2018-08-29
US62/724,596 2018-08-29
PCT/US2019/048922 WO2020047327A2 (en) 2018-08-29 2019-08-29 Flt3l-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075517A Division JP2024096361A (ja) 2018-08-29 2024-05-07 Ｆｌｔ３ｌ系キメラタンパク質

Publications (3)

Publication Number Publication Date
JP2022512540A true JP2022512540A (ja) 2022-02-07
JPWO2020047327A5 JPWO2020047327A5 (https=) 2022-09-06
JP2022512540A5 JP2022512540A5 (https=) 2022-09-06

Family

ID=69643788

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511583A Pending JP2022512540A (ja) 2018-08-29 2019-08-29 Ｆｌｔ３ｌ系キメラタンパク質
JP2024075517A Withdrawn JP2024096361A (ja) 2018-08-29 2024-05-07 Ｆｌｔ３ｌ系キメラタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075517A Withdrawn JP2024096361A (ja) 2018-08-29 2024-05-07 Ｆｌｔ３ｌ系キメラタンパク質

Country Status (9)

Country Link
US (1) US20240122983A1 (https=)
EP (1) EP3843755A4 (https=)
JP (2) JP2022512540A (https=)
CN (1) CN112888711A (https=)
AU (1) AU2019333175A1 (https=)
CA (1) CA3109352A1 (https=)
IL (1) IL281088A (https=)
MX (1) MX2021002289A (https=)
WO (1) WO2020047327A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210687A (es) * 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
JP2023506501A (ja) * 2019-12-16 2023-02-16 ワシントン・ユニバーシティ キメラ抗原受容体樹状細胞（ｃａｒ－ｄｃ）ならびにこれを作製および使用する方法
WO2022089418A1 (zh) * 2020-10-26 2022-05-05 信达生物制药(苏州)有限公司 重组截短FLT3配体与人抗体Fc的融合蛋白
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
WO2017059168A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2017099474A1 (ko) * 2015-12-08 2017-06-15 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자; FLT3L-TRAIL 융합 유전자; ＴＧＦ－β 발현을 억제하는 ｓｈＲＮＡ; 및 HSP 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물
US20180094046A1 (en) * 2012-09-11 2018-04-05 The Texas A&M University System Mosaic chimeric viral vaccine{[s]] particle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1276501B9 (en) * 2000-04-25 2007-01-24 Immunex Corporation Method for treatment of tumors using photodynamic therapy
CN101198621A (zh) * 2005-01-25 2008-06-11 阿波罗生命科学有限公司 分子及其嵌合分子

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529102A (ja) * 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
US20180094046A1 (en) * 2012-09-11 2018-04-05 The Texas A&M University System Mosaic chimeric viral vaccine{[s]] particle
WO2017059168A1 (en) * 2015-10-01 2017-04-06 Heat Biologics, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2017099474A1 (ko) * 2015-12-08 2017-06-15 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자; FLT3L-TRAIL 융합 유전자; ＴＧＦ－β 발현을 억제하는 ｓｈＲＮＡ; 및 HSP 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 58, JPN6023030925, 1998, pages 380 - 383, ISSN: 0005232228 *
J. IMMUNOL., vol. 163, no. 3, JPN6023030926, 1999, pages 1289 - 1297, ISSN: 0005119365 *
MOLECULAR THERAPY, vol. 9, no. 5, JPN6023030924, 2004, pages 674 - 681, ISSN: 0005232227 *
VACCINE, vol. 30, JPN6023030928, 2012, pages 1624 - 1635, ISSN: 0005119366 *

Also Published As

Publication number Publication date
CA3109352A1 (en) 2020-03-05
EP3843755A4 (en) 2022-08-31
WO2020047327A2 (en) 2020-03-05
JP2024096361A (ja) 2024-07-12
MX2021002289A (es) 2021-05-27
IL281088A (en) 2021-04-29
US20240122983A1 (en) 2024-04-18
AU2019333175A1 (en) 2021-03-04
CN112888711A (zh) 2021-06-01
EP3843755A2 (en) 2021-07-07
WO2020047327A3 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
JP7260477B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP7121029B2 (ja) Ｃｓｆ１ｒベースのキメラタンパク質
US20240122983A1 (en) Flt3l-based chimeric proteins
JP2022522479A (ja) 併用療法
JP2022512541A (ja) Ｐｄ－１系キメラタンパク質を含む併用療法
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
US11896618B2 (en) FLT3L-based chimeric proteins
JP2022532430A (ja) Ｎｋ細胞指向性キメラタンパク質
US20240299492A1 (en) Combination therapies with sirp alpha-based chimeric proteins
JP2022512539A (ja) 併用療法
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
US20230048633A1 (en) Tgfbr2-based chimeric proteins
JP2022503621A (ja) Ｔｉｍ－３系キメラタンパク質を含む併用療法
RU2792239C2 (ru) Химерные белки на основе csf1r
HK40101388A (en) Vsig8-based chimeric proteins
CN117355336A (zh) 基于SIRP α的嵌合蛋白的联合疗法
HK40019689B (en) Vsig8-based chimeric proteins
HK40019689A (en) Vsig8-based chimeric proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611